PROJECT NAME

Development of early warning features and guidance in the area of pricing through the EURIPID database

SUMMARY

Seven national bodies have teamed up to offer guidance in the area of pricing through the EURIPID database and develop early warning features, based on competition cases. EURIPID provides information on medicines and their prices in a standardised, continuously updated format. As of May 2022, information was available for 29 countries.
The existing EURIPID database will be completed with functionalities to enable early warning for the national competent authorities in charge of pricing and reimbursement of medicinal products in case of excessing pricing. Based on the new functionalities of the EURIPID website certain commercial practices of pharmaceutical companies will be addressed and quick check format analyses, so called policy briefs will be prepared. The analytical activities will include the monitoring of strategic sequencing of price increases or of threats to delist products.
Finally, with hosting or attending a number of webinars/workshops the cooperation between authorities to address the challenges due to certain commercial practices will be strengthened on the one hand, and on the other hand the dialogue on pharmaceutical pricing topics with stakeholders of the pharmaceutical sector will be continued in the established “Stakeholder Dialogue Format”.

DURATION OF THE PROJECT

1.3.2023 – 31.8.2025

BUDGET

EUR 375.000
EC co-financing EUR 300.000 € (80%)

PARTNERS

7 Member States
Coordinator: NEAK (Hungary)
Beneficiary partners: INFARMED (Portugal), RIZIV (Belgium), JAZMP (Slovenia), GÖG (Austria), NCPRMP (Bulgaria), AOTMiT (Poland).

ROLE OF JAZMP

As part of the EURIPID network JAZMP will participate in development of early warning features and guidance in the area of pricing through the EURIPID database.

WEB PAGE

https://euripid.eu

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HaDEA). Neither the European Union nor HaDEA can be held responsible for them.

Scroll to Top